Clinton Snow
Director/Board Member at ICETANA LIMITED
Profile
Clinton Snow is currently a Non-Executive Director at Dimerix Ltd., PolyActiva Pty Ltd., and iCetana Ltd.
He completed his undergraduate degree at the University of Melbourne.
Clinton Snow active positions
Companies | Position | Start |
---|---|---|
ICETANA LIMITED | Director/Board Member | 2022-02-07 |
DIMERIX LIMITED | Director/Board Member | 2023-04-30 |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Director/Board Member | - |
Training of Clinton Snow
University of Melbourne | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
DIMERIX LIMITED | Health Technology |
ICETANA LIMITED | Technology Services |
Private companies | 1 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Stock Market
- Insiders
- Clinton Snow